PharmaCyte Biotech shares surge 77.80% intraday after FDA approval excitement and Femasys monetization boost cash to $20M.

PharmaCyte Biotech surged 77.80% intraday following a combination of FDA-related optimism and strategic monetization of its stake in Femasys, which boosted cash reserves to $20M. The move aligns with recent news highlighting the company’s progress in cancer therapy advancements and a significant liquidity improvement from $13.3M to $20M. Analysts attribute the sharp rally to speculative trading driven by regulatory milestones and capital restructuring, despite underlying financial challenges like a $8.36M net loss. The biotech sector’s volatile nature and short-term bullish momentum further amplified the stock’s extreme intraday gains.